Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-14
2007-08-14
Wehbe, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C435S325000
Reexamination Certificate
active
10395712
ABSTRACT:
Methods and pharmaceutical compositions for modifying cells of a mammalian recipient with DNA encoding a secreted protein such as human interferon in situ are provided. The methods include forming a secreted protein expression system in vivo or ex vivo and administering the expression system to the mammalian recipient. The expression system and methods are useful for the localized and systemic delivery of interferons in situ.
REFERENCES:
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5518913 (1996-05-01), Massie et al.
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5552309 (1996-09-01), March
patent: 5585237 (1996-12-01), Oppermann et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5662896 (1997-09-01), Barber et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5677178 (1997-10-01), McCormick
patent: 5698531 (1997-12-01), Nabel et al.
patent: 5700470 (1997-12-01), Saito et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5707969 (1998-01-01), Nabel et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 5831062 (1998-11-01), Taylor et al.
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5846945 (1998-12-01), McCormick
patent: 5849561 (1998-12-01), Falck-Pedersen
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5856181 (1999-01-01), McCormick
patent: 5866552 (1999-02-01), Wilson et al.
patent: 5876974 (1999-03-01), Gregory
patent: 5880102 (1999-03-01), George et al.
patent: 5882877 (1999-03-01), Gregory et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 5935935 (1999-08-01), Connelly et al.
patent: 5952221 (1999-09-01), Kurtzman et al.
patent: 5972706 (1999-10-01), McCormick
patent: 5981225 (1999-11-01), Kochanek et al.
patent: 5981274 (1999-11-01), Tyrrell et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 5997859 (1999-12-01), Barber et al.
patent: 6001557 (1999-12-01), Wilson et al.
patent: 6013638 (2000-01-01), Crystal et al.
patent: 6020191 (2000-02-01), Scaria et al.
patent: 6033885 (2000-03-01), Latta et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6040174 (2000-03-01), Imler et al.
patent: 6057158 (2000-05-01), Chamberlain et al.
patent: 6063622 (2000-05-01), Chamberlain et al.
patent: 6066624 (2000-05-01), Woo et al.
patent: 6080569 (2000-06-01), Graham et al.
patent: 6083750 (2000-07-01), Chamberlain et al.
patent: 6093567 (2000-07-01), Gregory et al.
patent: 6100086 (2000-08-01), Kaplan et al.
patent: 6120764 (2000-09-01), Graham et al.
patent: 6136594 (2000-10-01), Dalemans et al.
patent: 6140087 (2000-10-01), Graham et al.
patent: 6140103 (2000-10-01), Einerhand et al.
patent: 6203975 (2001-03-01), Wilson et al.
patent: 6204052 (2001-03-01), Bout et al.
patent: 6204060 (2001-03-01), Mehtali et al.
patent: 6210939 (2001-04-01), Gregory et al.
patent: 6218180 (2001-04-01), Kurtzman et al.
patent: 6228646 (2001-05-01), Hardy
patent: 6241982 (2001-06-01), Barber et al.
patent: 6281010 (2001-08-01), Gao et al.
patent: 6297219 (2001-10-01), Nabel et al.
patent: 6303362 (2001-10-01), Kay et al.
patent: 6312681 (2001-11-01), Engler et al.
patent: 6312946 (2001-11-01), Yeh et al.
patent: 6348450 (2002-02-01), Tang et al.
patent: 6531456 (2003-03-01), Kurtzman et al.
patent: 6696423 (2004-02-01), Barsoum et al.
patent: 2002/0006395 (2002-01-01), Perricaudet et al.
patent: 2002/0034505 (2002-03-01), Nabel et al.
patent: 2002/0197236 (2002-12-01), Nabel et al.
patent: 2004/0086486 (2004-05-01), Barsoum et al.
patent: 2004/0265288 (2004-12-01), Gilman
patent: B-37570/93 (1993-10-01), None
patent: B-61444/94 (1994-09-01), None
patent: B-65721/94 (1994-11-01), None
patent: 704919 (1995-06-01), None
patent: 716508 (1997-01-01), None
patent: 0 070 906 (1986-10-01), None
patent: 0 707 071 (1995-08-01), None
patent: 0 777 740 (1997-06-01), None
patent: 0 804 601 (1997-11-01), None
patent: 57-130998 (1982-08-01), None
patent: 8506970 (1996-07-01), None
patent: 8-238092 (1996-09-01), None
patent: WO 85/05125 (1985-11-01), None
patent: WO 88/00971 (1988-02-01), None
patent: WO 90/11734 (1990-10-01), None
patent: WO 93/00051 (1993-01-01), None
patent: WO 93/00052 (1993-01-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO 94/12649 (1994-06-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/20146 (1994-09-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 94/28152 (1994-12-01), None
patent: WO 94/28938 (1994-12-01), None
patent: WO 95/14785 (1995-06-01), None
patent: WO 95/16784 (1995-06-01), None
patent: WO 95/34671 (1995-12-01), None
patent: WO96/06939 (1996-03-01), None
patent: WO96/06940 (1996-03-01), None
patent: WO 96/12030 (1996-04-01), None
patent: WO 97/00947 (1997-01-01), None
patent: WO 97/20943 (1997-06-01), None
patent: WO 97/21826 (1997-06-01), None
patent: WO 97/32991 (1997-09-01), None
patent: WO 97/42323 (1997-11-01), None
patent: WO 98/39418 (1998-09-01), None
patent: WO 98/53087 (1998-11-01), None
patent: WO 99/41398 (1999-08-01), None
patent: WO 00/72679 (2000-12-01), None
Gorzilglia et al. (1996) J. Virol., vol. 70 (6), 4173-4178.
Verma et al. (1997) Nature, vol. 389, 239-242.
Marshall et al. (1995) Science, vol. 269, 1050-1055.
Orkin et al. (1995) “Report and Recommendation to the NIH”, p. 1-23.
Deonarian et al. (1998) Exp. Opin. Ther. Patents, vol. 9(1), 53-69.
Miller et al. (1995) FASEB, vol. 9, 90-99.
Lusky, M., “Good manufacturing practice production of adenoviral vectors for clinical trials”Human Gene Therapy16: 281-291 (Mar. 2005).
Einhorn et al., “Why Do So Many Cancer Patients Fail to Respond to Interferon Therapy?”Journal of Interferon and Cytokine Research16:275-281 (1996).
Johns et al., “Antiproliferative Potencies of Interferons on Melanoma Cell Lines and Xenografts: Higher Efficacy of Interferon β”Journal of the National Cancer Institutevol. 84, No. 15: 1185-1190 (Aug. 5, 1992).
Garbe et al., “Antitumor Activities of Interferon Alpha, Beta, and Gamma and Their Combinations on Human Melanoma Cells In Vitro: Changes of Proliferation, Melanin Synthesis, and Immunophenotype”The Journal of Investigative Dermatologyvol. 95, No. 6, Supplement: 231S-237S (1990).
Arbaje et al., “Antiproliferative Effects of Interferons -α and -β in Combination with 5-Fluorouracil, Cisplatin, and Cis- and Trans-Retinoic Acid in Three Human Lung Carcinoma Cell lines”Journal of Interferon Research13:25-32 (1993).
Rosenblum et al., “Growth Inhibitory Effects of Interferon-β But Not Interferon-α on Human Glioma Cells: Correlation of Receptor Binding, 2′, 5′ -Oligoadenylate Synthetase and Protein Kinase Activity”Journal of Interferon Research10:141-151 (1990).
Hertzog et al., “Comparative Antiproliferative and Receptor Binding Activities of Interferons α and β on Lymphoblastoid and Melanoma Cells”Biochemistry Internationalvol. 22, No. 6: 1095-1102 (1990).
Borden et al., “Second-generation Interferons For Cancer: Clinical Targets”seminars in Cancer Biologyvol. 10: 125-144 (2000).
Hansen et al., “Current Status of Interferons In the Treatment of Cancer”Oncology, vol. 6, No. 11: 19-24 (1992).
Dorr, “Interferon-α in Malignant and Viral Diseases”Drugs45 (2): 177-211 (1993).
Wadler et al., “Antineoplastic Activity of The Combination of Interferon and Cytotoxic Agents against Experimental and Human Malignancies: A Review”Cancer Research50, 3473-3486, (1990).
Minakuchi et al., “Remarkable and Persistent Shrinkage of Uterine Leiomyoma Associated with Interferon alfa Treatment for Hepatitis”The Lancetvol. 353: 2127-2128 (1999).
Schiller et al., “Phase II Trial of a Combination of Interferon-βser and Interferon-γ in Patients with Ad
Barsoum James G
Qin Albert X
Biogen Idec MA Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
Wehbe Anne M.
LandOfFree
Methods and compositions for therapies using genes encoding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for therapies using genes encoding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for therapies using genes encoding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3860579